← back to search

Kim Lauper

University Hospital of Geneva ·
Area of research
Rheumatology · Immunology
Research interest
Research interests include Rheumatoid Arthritis Research and Therapies, Spondyloarthritis Studies and Treatments, Biosimilars and Bioanalytical Methods, and Systemic Lupus Erythematosus Research.
h-index
23
citations
4,131
works
114
NIH funding
primary concept
email

Recent publications

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With <scp>JAK</scp> Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
Arthritis & Rheumatology 2025cited by 15position: lastdoi
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
PubMed 2025cited by 6position: middledoi
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
PubMed 2024cited by 18position: middledoi
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)
Annals of the Rheumatic Diseases 2023cited by 22position: lastdoi
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Annals of the Rheumatic Diseases 2022cited by 1,731position: middledoi
Global epidemiology of rheumatoid arthritis
Nature Reviews Rheumatology 2022cited by 703position: lastdoi
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
Annals of the Rheumatic Diseases 2022cited by 214position: middledoi
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
Annals of the Rheumatic Diseases 2022cited by 142position: firstdoi
Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab
JAMA Neurology 2022cited by 86position: middledoi
Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study
Clinical Infectious Diseases 2021cited by 124position: middledoi
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
Lara D. Veeken 2020cited by 93position: middledoi
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus
Autoimmunity Reviews 2020cited by 70position: middledoi
OP0231 COMPARATIVE EFFECTIVENESS OF JAK-INHIBITORS, TNF-INHIBITORS, ABATACEPT AND IL-6 INHIBITORS IN AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-POT” STUDY)
Annals of the Rheumatic Diseases 2020cited by 31position: firstdoi
Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic
Annals of the Rheumatic Diseases 2020cited by 8position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Axel Finckh · University of Geneva4 papers (2020–2022) · 2 papers (2021–2022) · 2 papers (2021–2022)Alessandro Sette · University of California System2 papers (2021–2022)Arnaud M. Didierlaurent · University of Geneva2 papers (2021–2022)Christiane S. Eberhardt · University of Geneva2 papers (2021–2022)Anja Strangfeld · German Rheumatism Research Centre2 papers (2020–2022)Rachel Goldstein · Palo Alto University2 papers (2021–2022)Patrice H. Lalive · California University of Pennsylvania2 papers (2021–2022)Kimme L Hyrich · University of Manchester2 papers (2020–2022)J. W. J. Bijlsma · University of Groningen2 papers (2020–2022)Gautier Bréville · California University of Pennsylvania2 papers (2021–2022)Alba Grifoni · La Jolla Institute for Immunology2 papers (2021–2022) · 1 papers (2020–2020) · 1 papers (2022–2022)Žiga Rotar · Amgen (United States)1 papers (2020–2020)Karel Pavelká · Utrecht University1 papers (2020–2020) · 1 papers (2022–2022) · 1 papers (2020–2020)Marco Sebastiani · University Hospital Frankfurt1 papers (2022–2022)